ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe
November 27, 2024 04:30 ET
|
Advanz Pharma
ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The conditional marketing authorisation...
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)
September 03, 2024 04:00 ET
|
Advanz Pharma
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...
Primary Biliary Cholangitis Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Ipsen, Zydus, COUR, Calliditas, CymaBay, Mirum, Intercept, Escient, GlaxoSmithKline
December 06, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Primary Biliary Cholangitis Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Ipsen, Zydus, COUR,...
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
January 01, 2021 19:15 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
Global Primary Biliary Cholangitis Treatment Market to surpass US$ 10,820.8 million by 2026 - Coherent Market Insights
March 19, 2019 08:35 ET
|
CMI
SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global Primary Biliary Cholangitis Treatment Market was valued at US$ 526.4 million in 2017, and is projected...
CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
May 31, 2016 07:00 ET
|
CymaBay Therapeutics, Inc.
Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacyLarge...